Scribe Biosciences, Inc.
Doing business as Scribe Biosciences Inc.
- UEI
- QMCJSMLF9TP1
- CAGE
- 7MGL5
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| High throughput antibody discovery against cell membrane bound target proteins using innovative MOD technology for… | National Institute of Allergy and Infectious Diseases | $300,000 | |
| Microenvironment on demand (MOD): a platform for single-cell cytotoxicity assays - abstract scribe biosciences are… | National Cancer Institute | $699,994 | |
| A platform for engineering peptide ligase for building next generation peptide therapeutics. | National Institute of General Medical Sciences | $225,000 | |
| A platform for integrating cell signaling and single cell transcriptomics. | National Human Genome Research Institute | $350,000 | |
| Sbir phase i: controlled organoid synthesis with fluorescence-activated cell printing | Division of Industrial Innovation | $225,000 |
About Scribe Biosciences, Inc.
Scribe Biosciences, Inc. is a for-profit corporate entity that provides research and development services related to biomedical engineering, microfluidics, genomics, and cell therapy to the federal government through grant awards. The company has developed a proprietary droplet microfluidics platform called Microenvironment on Demand (MOD) for assembling high-throughput single-cell assays.
Through past federal grants, Scribe Biosciences has provided research and development services related to infectious disease, cancer biology, peptide therapeutics, cell signaling, and organoid engineering. This includes a $300,000 project grant from the National Institute of Allergy and Infectious Diseases to develop high-throughput antibody discovery against membrane proteins, a $699,994 project grant from the National Cancer Institute to build single-cell cytotoxicity assays for testing CAR T cell therapies, and project grants from the National Institute of General Medical Sciences, National Human Genome Research Institute, and National Science Foundation related to peptide engineering, cell signaling, transcriptomics, and organoid printing. The federal funding agencies providing these awards include the National Institutes of Health, National Science Foundation, and Department of Health and Human Services. Scribe's work through these grants involves utilizing its MOD microfluidics platform to advance biomedical research and development in areas such as infectious disease, cancer biology, genomics, and cell therapy.
Quick answers
What is Scribe Biosciences, Inc.'s UEI?
Scribe Biosciences, Inc.'s Unique Entity ID (UEI) in SAM.gov is QMCJSMLF9TP1.
What is Scribe Biosciences, Inc.'s CAGE code?
Scribe Biosciences, Inc.'s CAGE code is 7MGL5.
What is Scribe Biosciences, Inc.'s primary NAICS code?
Scribe Biosciences, Inc.'s primary NAICS code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)).
Is Scribe Biosciences, Inc. registered in SAM.gov?
Scribe Biosciences, Inc.'s SAM.gov registration expired on July 12, 2024.
What is Scribe Biosciences, Inc.'s most recent federal award?
Scribe Biosciences, Inc.'s most recent federal grant award is High throughput antibody discovery against cell membrane bound target proteins using innovative MOD technology for… (R43AI177129), from National Institute of Allergy and Infectious Diseases, on August 1, 2023.
On GovTribe
See Scribe Biosciences, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors